Clinical Trial Update: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 pediatric study evaluating guselkumab in moderately to severely active ulcerative colitis is active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colitis, Ulcerative | Phase 3 | Status: ACTIVE_NOT_RECRUITING